雅努斯酶抑制剂治疗白发症:一个叙述性综述
Renee D Haughton1, Samantha M Herbert1, Antonio Ji-Xu1
1Department of Dermatology, University of California, Davis, 3301 C St., Sacramento, United States.
Indian journal of dermatology, venereology and leprology
|July 12, 2023
概括
简氏激酶 (JAK) 抑制剂在治疗白发症方面表现有前途,口服JAK抑制剂在对其他治疗有抗性的患者中显示出头发的再生. 局部的JAK抑制剂产生了不那么有利的结果.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 雅努斯酶 (JAK) 和信号转换器和转录激活器 (STAT) 途径与脱发区病原发生有关.
- 这一途径代表了管理多发性脱发症的重要治疗目标.
研究的目的:
- 为提供Janus激酶 (JAK) 抑制剂用于白发症治疗的叙述性综述.
- 总结目前关于JAK抑制剂在白发症的有效性和局限性的证据.
主要方法:
- 临床试验和较小的研究对JAK抑制剂在脱发区域的综述.
- 对口服和局部JAK抑制剂的数据分析,包括FDA批准和正在研究的药物.
主要成果:
- 口服JAK抑制剂,包括巴里西提尼布,托法西提尼布,鲁克索利提尼布和里特莱西提尼布,在促进头发再生和缓解方面表现出有效性.
- 这些药物即使在治疗不耐治疗的脱发症患者中也是有效的.
- 局部JAK抑制剂的成功程度有限,有几项试验提前终止.
结论:
- 雅努斯酶 (JAK) 抑制剂是耐火性脱发症的有价值的治疗选择.
- 需要进一步的研究来评估长期的安全性,局部JAK抑制剂的疗效,以及治疗反应的预测生物标志物.
相关概念视频
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
Accessory Structures of the Skin: Hair Growth and Types
1.5K
Hair growth begins with the production of keratinocytes by the basal cells of the hair bulb. As new cells are deposited at the hair bulb, the hair shaft is pushed through the follicle toward the surface. Keratinization is completed as the cells are pushed to the skin surface to form the shaft of hair that is externally visible. The external hair is completely dead and composed entirely of keratin. Hair can be cut or shaven without damaging the hair structure because the cut is superficial. Most...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
175
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175
Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K


